HPV Vaccine Safety and Effectiveness
HPV vaccines are very safe. Scientific research shows the benefits of HPV vaccination far outweigh the potential risks. Like all medical interventions, vaccines can have some side effects. More than 80 million doses of HPV vaccine have been distributed since the vaccine was introduced in 2006. The most common side effects associated with HPV vaccines are mild, and include pain, redness, or swelling in the arm where the shot was given.
All vaccines used in the United States, including HPV vaccines, are required to go through years of extensive safety testing before they are licensed by the U.S. Food and Drug Administration (FDA). During clinical trials conducted before they were licensed:
- 9-valent HPV vaccine was studied in more than 15,000 males and females
- Quadrivalent HPV vaccine was studied in more than 29,000 males and females
- Bivalent HPV vaccine was studied in more than 30,000 females
Each HPV vaccine was found to be safe and effective.
Fainting (syncope) can occur after any medical procedure, including vaccination. Recent data suggest that syncope after any vaccination is more common in adolescents. Adolescents and adults should be seated or lying down during vaccination. Providers are encouraged to observe patients in seated or lying positions for 15 minutes after vaccination. This is to prevent any injuries that could occur from a fall during a syncopal event.
The HPV vaccine works extremely well. In the four years after the vaccine was recommended in 2006 in the United States, quadrivalent type HPV infections in teen girls decreased by 56% and decreases in prevalence have also been observed in women in their early 20s. Research has also shown that fewer teens are getting genital warts since HPV vaccines have been in use in the United States. Decreases in vaccine-type prevalence, genital warts, and cervical dysplasia have also been observed in other countries with HPV vaccination programs.
There are no data to suggest HPV vaccines will treat existing diseases or conditions caused by HPV. However, people can still get protection from HPV types in the vaccine that have not been acquired.
Cervical cancer screening is recommended for women beginning at age 21 years and continuing through age 65 years. Women who have received the HPV vaccine series should still be screened for cervical cancer beginning at age 21 years, in accordance with currently published cervical cancer screening guidelines.
Studies suggest that HPV vaccines offer long-lasting protection against HPV infection and therefore disease caused by HPV infection. Studies of the bivalent and quadrivalent vaccines have followed vaccinated individuals for eight to ten years and have found no evidence of protection decreasing over time. Duration of protection provided by HPV vaccination will continue to be studied.